Longitudinal proteomic investigation of COVID-19 vaccination
Received date: 01 Nov 2022
Accepted date: 28 Dec 2022
Copyright
Although the development of COVID-19 vaccines has been a remarkable success, the heterogeneous individual antibody generation and decline over time are unknown and still hard to predict. In this study, blood samples were collected from 163 participants who next received two doses of an inactivated COVID-19 vaccine (CoronaVac®) at a 28-day interval. Using TMT-based proteomics, we identified 1,715 serum and 7,342 peripheral blood mononuclear cells (PBMCs) proteins. We proposed two sets of potential biomarkers (seven from serum, five from PBMCs) at baseline using machine learning, and predicted the individual seropositivity 57 days after vaccination (AUC = 0.87). Based on the four PBMC’s potential biomarkers, we predicted the antibody persistence until 180 days after vaccination (AUC = 0.79). Our data highlighted characteristic hematological host responses, including altered lymphocyte migration regulation, neutrophil degranulation, and humoral immune response. This study proposed potential blood-derived protein biomarkers before vaccination for predicting heterogeneous antibody generation and decline after COVID-19 vaccination, shedding light on immunization mechanisms and individual booster shot planning.
Key words： COVID-19; vaccination; proteomics; neutralizing antibodies (NAbs); machine learning
Yingrui Wang , Qianru Zhu , Rui Sun , Xiao Yi , Lingling Huang , Yifan Hu , Weigang Ge , Huanhuan Gao , Xinfu Ye , Yu Song , Li Shao , Yantao Li , Jie Li , Tiannan Guo , Junping Shi . Longitudinal proteomic investigation of COVID-19 vaccination[J]. Protein & Cell, 2023 , 14(9) : 668 -682 . DOI: 10.1093/procel/pwad004
| 1 |
Ai J, Guo J, Zhang H et al. Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling. Cell Discov 2022;8:114.
|
| 2 |
Arunachalam PS, Scott MKD, Hagan T et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 2021;596:410–416.
|
| 3 |
Bi X, Liu W, Ding X et al. Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19. Cell Rep 2021;38:110271.
|
| 4 |
Botham KM, Wheeler-Jones CP. Postprandial lipoproteins and the molecular regulation of vascular homeostasis. Prog Lipid Res 2013;52:446–464.
|
| 5 |
Brannagan TH 3rd, Auer-Grumbach M, Berk JL et al. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis 2021;16:204.
|
| 6 |
C DA-M, Couto AES, Campos LCB et al. MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients. Biomed Pharmacother 2021;142:112067.
|
| 7 |
Chen TQ, Guestrin C. XGBoost: a scalable tree boosting system. Kdd’16: Proceedings of the 22nd Acm Sigkdd International Conference on Knowledge Discovery and Data Mining, 2016, 785–794.
|
| 8 |
Chen Y, Yin S, Tong X et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clin Microbiol Infect 2022;28:410–418.
|
| 9 |
Costa Clemens SA, Weckx L, Clemens R et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 2022;399:521–529.
|
| 10 |
Davey A, McAuley DF, O’Kane CM. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur Respir J 2011;38:959–970.
|
| 11 |
de Souza JG, Starobinas N, Ibanez OCM. Unknown/enigmatic functions of extracellular ASC. Immunology 2021;163:377–388.
|
| 12 |
Falsey AR, Frenck RW Jr,, Walsh EE et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med 2021;385:1627–1629.
|
| 13 |
Gao H, Zhang F, Liang S et al. Accelerated lysis and proteolytic digestion of biopsy-level fresh-frozen and FFPE tissue samples using pressure cycling technology. J Proteome Res 2020;19:1982–1990.
|
| 14 |
Guerra-De-Blas PDC, Bobadilla-Del-Valle M, Sada-Ovalle I et al. Simvastatin enhances the immune response against mycobacterium tuberculosis. Front Microbiol 2019;10:2097.
|
| 15 |
Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000;96:3049–3055.
|
| 16 |
Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf 2013;14:7.
|
| 17 |
Iizuka Y, Cichocki F, Sieben A et al. UNC-45A Is a nonmuscle myosin IIA chaperone required for NK cell cytotoxicity via control of lytic granule secretion. J Immunol 2015;195:4760–4770.
|
| 18 |
Kabra NH, Kang C, Hsing LC et al. T cell-specific FADD-deficient mice: FADD is required for early T cell development. Proc Natl Acad Sci USA 2001;98:6307–6312.
|
| 19 |
Karlsson M, Zhang C, Mear L et al. A single-cell type transcriptomics map of human tissues. Sci Adv 2021;7:eabh2169.
|
| 20 |
Karmaus PW, Shi M, Perl S et al. Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol. JCI Insight 2019;4:e131530.
|
| 21 |
Kramer A, Green J, Pollard J et al. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 2014;30:523–530.
|
| 22 |
Krause PR, Fleming TR, Peto R et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet 2021;398:1377–1380.
|
| 23 |
Lee A, Wong SY, Chai LYA et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022;376:e068632.
|
| 24 |
Liu J, Wang J, Xu J et al. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discov 2021;7:99.
|
| 25 |
Ma ML, Shi DW, Li Y et al. Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. Cell Discov 2021;7:67.
|
| 26 |
Meizlish ML, Pine AB, Bishai JD et al. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Adv 2021;5:1164–1177.
|
| 27 |
Messner CB, Demichev V, Wendisch D et al. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst 2020;11:11–24.e4.
|
| 28 |
Newman AM, Liu CL, Green MR et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015;12:453–457.
|
| 29 |
Otasek D, Morris JH, Boucas J et al. Cytoscape automation: empowering workflow-based network analysis. Genome Biol 2019;20:185.
|
| 30 |
Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 2021;21:475–484.
|
| 31 |
Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010;125:S41–S52.
|
| 32 |
Serrador JM, Nieto M, Alonso-Lebrero JL et al. CD43 interacts with moesin and ezrin and regulates its redistribution to the uropods of T lymphocytes at the cell-cell contacts. Blood 1998;91:4632–4644.
|
| 33 |
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184:861–880.
|
| 34 |
Shen B, Yi X, Sun Y et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 2020;182:59–72.e15.
|
| 35 |
Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463–516.
|
| 36 |
Ueland T, Holter JC, Holten AR et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect 2020;81:e41–e43.
|
| 37 |
van der Graaf R, Browne JL, Baidjoe AY. Vaccine equity: past, present and future. Cell Rep Med 2022;3:100551.
|
| 38 |
Wang Y, Ning X, Gao P et al. Inflammasome activation triggers caspase-1-mediated cleavage of cGAS to regulate responses to DNA virus infection. Immunity 2017;46:393–404.
|
| 39 |
Wang Y, Wang X, Luu LDW et al. Proteomic and metabolomic signatures associated with the immune response in healthy individuals immunized with an inactivated SARS-CoV-2 vaccine. Front Immunol 2022;13:848961.
|
| 40 |
Xue J-B, Lai D-Y, Jiang H-W et al. Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated virus vaccine against the Omicron variant. Cell Discov 2022;8:15.
|
| 41 |
Zeng G, Wu Q, Pan H et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis 2022;22:483–495.
|
| 42 |
Zhang H, Hu Y, Jiang Z et al. Single-cell sequencing and immune function assays of peripheral blood samples demonstrate positive responses of an inactivated SARS-CoV-2 vaccine. SSRN. 2021.
|
| 43 |
Zhao X, Li D, Ruan W et al. Effects of a prolonged booster interval on neutralization of omicron variant. N Engl J Med 2022;386:894–896.
|
| 44 |
Zhou Y, Zhou B, Pache L et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019;10:1523.
|
/
| 〈 |
|
〉 |